Michael W Calik1. 1. Center for Narcolepsy, Sleep and Health Research, Department of Biobehavioral Health Science, University of Illinois at Chicago, Chicago, IL.
Abstract
OBJECTIVE: To review the efficacy of current treatment options for adults with obstructive sleep apnea (OSA). METHODS: Review of the literature. RESULTS: OSA, characterized by repetitive ≥ 10-second interruptions (apnea) or reductions (hypopnea) in airflow, is initiated by partial or complete collapse in the upper airway despite respiratory effort. When left untreated, OSA is associated with comorbid conditions, such as cardiovascular and metabolic diseases. The current "gold standard" treatment for OSA is continuous positive air pressure (CPAP), which pneumatically stabilizes the upper airways. CPAP has proven efficacy and potential cost savings via decreases in health comorbidities and/or motor-vehicle crashes. However, CPAP treatment is not well-tolerated due to various side effects, and adherence among OSA subjects can be as low as 50% in certain populations. Other treatment options for OSA include improving CPAP tolerability, increasing CPAP adherence through patient interventions, weight loss/exercise, positional therapy, nasal expiratory positive airway pressure, oral pressure therapy, oral appliances, surgery, hypoglossal nerve stimulation, drug treatment, and combining 2 or more of the aforementioned treatments. Despite the many options available to treat OSA, none of them are as efficacious as CPAP. However, many of these treatments are tolerable, and adherence rates are higher than those of the CPAP, making them a more viable treatment option for long-term use. CONCLUSION: Patients need to weigh the benefits and risks of available treatments for OSA. More large randomized controlled studies on treatments or combination of treatments for OSA are needed that measure parameters such as treatment adherence, apnea-hypopnea index, oxygen desaturation, subjective sleepiness, quality of life, and adverse events.
OBJECTIVE: To review the efficacy of current treatment options for adults with obstructive sleep apnea (OSA). METHODS: Review of the literature. RESULTS: OSA, characterized by repetitive ≥ 10-second interruptions (apnea) or reductions (hypopnea) in airflow, is initiated by partial or complete collapse in the upper airway despite respiratory effort. When left untreated, OSA is associated with comorbid conditions, such as cardiovascular and metabolic diseases. The current "gold standard" treatment for OSA is continuous positive air pressure (CPAP), which pneumatically stabilizes the upper airways. CPAP has proven efficacy and potential cost savings via decreases in health comorbidities and/or motor-vehicle crashes. However, CPAP treatment is not well-tolerated due to various side effects, and adherence among OSA subjects can be as low as 50% in certain populations. Other treatment options for OSA include improving CPAP tolerability, increasing CPAP adherence through patient interventions, weight loss/exercise, positional therapy, nasal expiratory positive airway pressure, oral pressure therapy, oral appliances, surgery, hypoglossal nerve stimulation, drug treatment, and combining 2 or more of the aforementioned treatments. Despite the many options available to treat OSA, none of them are as efficacious as CPAP. However, many of these treatments are tolerable, and adherence rates are higher than those of the CPAP, making them a more viable treatment option for long-term use. CONCLUSION:Patients need to weigh the benefits and risks of available treatments for OSA. More large randomized controlled studies on treatments or combination of treatments for OSA are needed that measure parameters such as treatment adherence, apnea-hypopnea index, oxygen desaturation, subjective sleepiness, quality of life, and adverse events.
Authors: Christopher E Kline; E Patrick Crowley; Gary B Ewing; James B Burch; Steven N Blair; J Larry Durstine; J Mark Davis; Shawn D Youngstedt Journal: Sleep Date: 2011-12-01 Impact factor: 5.849
Authors: Simon A Joosten; Bradley A Edwards; Andrew Wellman; Anthony Turton; Elizabeth M Skuza; Philip J Berger; Garun S Hamilton Journal: Sleep Date: 2015-09-01 Impact factor: 5.849
Authors: Bradley A Edwards; James G Connolly; Lisa M Campana; Scott A Sands; John A Trinder; David P White; Andrew Wellman; Atul Malhotra Journal: Sleep Date: 2013-02-01 Impact factor: 5.849
Authors: Marijke Dieltjens; Marc J Braem; Anneclaire V M T Vroegop; Kristien Wouters; Johan A Verbraecken; Wilfried A De Backer; Paul H Van de Heyning; Olivier M Vanderveken Journal: Chest Date: 2013-11 Impact factor: 9.410
Authors: Amy M Sawyer; Tonya S King; Alexandra Hanlon; Kathy C Richards; Leon Sweer; Albert Rizzo; Terri E Weaver Journal: Sleep Breath Date: 2014-03-05 Impact factor: 2.816
Authors: Danny J Eckert; David P White; Amy S Jordan; Atul Malhotra; Andrew Wellman Journal: Am J Respir Crit Care Med Date: 2013-10-15 Impact factor: 21.405
Authors: Christopher E Kline; David M Reboussin; Gary D Foster; Thomas B Rice; Elsa S Strotmeyer; John M Jakicic; Richard P Millman; F Xavier Pi-Sunyer; Anne B Newman; Thomas A Wadden; Gary Zammit; Samuel T Kuna Journal: Sleep Date: 2016-02-01 Impact factor: 5.849
Authors: Gonzalo Labarca; Francisco Ortega; Alex Arenas; Tomas Reyes; Gabriel Rada; Jorge Jorquera Journal: BMJ Open Date: 2017-06-30 Impact factor: 2.692